Compile Data Set for Download or QSAR
Report error Found 859 for UniProtKB: O95251
TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730859(US20250122183, Example 072)
Affinity DataKi:  1.10nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730909(US20250122183, Example 122)
Affinity DataKi:  1.20nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM731000(US20250122183, Example 213)
Affinity DataKi:  1.70nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730834(US20250122183, Example 047)
Affinity DataKi:  1.90nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730901(US20250122183, Example 114)
Affinity DataKi:  2.10nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730908(US20250122183, Example 121)
Affinity DataKi:  2.10nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730858(US20250122183, Example 071)
Affinity DataKi:  2.20nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM731013(US20250122183, Example 226)
Affinity DataKi:  2.40nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730933((stereospecific Procedure): N-{6-[(3-cyclopropyl-1...)
Affinity DataKi:  2.40nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730990(US20250122183, Example 203)
Affinity DataKi:  3nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730988(US20250122183, Example 201)
Affinity DataKi:  3.40nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730782(US20250122183, Example 002)
Affinity DataKi:  3.5nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM731009(US20250122183, Example 222)
Affinity DataKi:  4nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730896(US20250122183, Example 109)
Affinity DataKi:  5nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730869(US20250122183, Example 082)
Affinity DataKi:  7.5nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730941(US20250122183, Example 154)
Affinity DataKi:  7.80nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580699(US11492346, Example 39)
Affinity DataKi:  8nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730831(US20250122183, Example 044)
Affinity DataKi:  9.80nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM653602(US11911372, Example 23 | US20240277683, Example 23)
Affinity DataIC50: 10.2nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM653602(US11911372, Example 23 | US20240277683, Example 23)
Affinity DataIC50: 10.2nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580784(US11492346, Example 129)
Affinity DataKi:  10.6nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730821(US20250122183, Example 034)
Affinity DataKi:  11.2nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730871(US20250122183, Example 084)
Affinity DataKi:  12.2nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730813(US20250122183, Example 026)
Affinity DataKi:  14.7nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730942(US20250122183, Example 155)
Affinity DataKi:  14.9nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730820(US20250122183, Example 033)
Affinity DataKi:  15.4nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580788(US11492346, Example 133)
Affinity DataKi:  19.2nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580710(US11492346, Example 50)
Affinity DataKi:  20nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580684(US11492346, Example 24)
Affinity DataKi:  20nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730866(US20250122183, Example 079)
Affinity DataKi:  25.2nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM653593(US11911372, Example 14 | US20240277683, Example 14)
Affinity DataIC50: 25.6nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730828(US20250122183, Example 041)
Affinity DataKi:  25.6nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM653593(US11911372, Example 14 | US20240277683, Example 14)
Affinity DataIC50: 25.6nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730829(US20250122183, Example 042)
Affinity DataKi:  26.7nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730837(US20250122183, Example 050)
Affinity DataKi:  28.4nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580675(US11492346, Example 15)
Affinity DataKi:  30nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580750(US11492346, Example 92)
Affinity DataKi:  30nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580731(US11492346, Example 71)
Affinity DataKi:  30nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM653649(US11911372, Example 71 | US20240277683, Example 71)
Affinity DataIC50: 35.4nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM653649(US11911372, Example 71 | US20240277683, Example 71)
Affinity DataIC50: 35.4nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730811(US20250122183, Example 023)
Affinity DataKi:  36.7nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM580774(US11492346, Example 119 | US20250122183, Example 0...)
Affinity DataKi:  37.7nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730849(US20250122183, Example 062)
Affinity DataKi:  38.1nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM653650(US11911372, Example 72 | US20240277683, Example 72)
Affinity DataIC50: 38.8nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM653650(US11911372, Example 72 | US20240277683, Example 72)
Affinity DataIC50: 38.8nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580707(US11492346, Example 47)
Affinity DataKi:  40nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580669(US11492346, Example 9 | US11492346, Example 90 | U...)
Affinity DataKi:  40nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580721(US11492346, Example 61)
Affinity DataKi:  40nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7(Human)
Pfizer

US Patent
LigandPNGBDBM580683(US11492346, Example 23)
Affinity DataKi:  40nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730865(US20250122183, Example 078)
Affinity DataKi:  40.2nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

Displayed 1 to 50 (of 859 total ) | Next | Last >>
Jump to: